Zuellig Pharma


Concise Prescribing Info
Hydrocortisone Na succinate
In situations requiring rapid & intense hormonal effect eg, acute adrenocortical insufficiency, bilateral adrenalectomy, severe shock, acute hypersensitivity reactions, overwhelming infections w/ severe toxicity, SLE in relapse, aspiration pneumonitis.
Dosage/Direction for Use
Adult Initially 100-500 mg IV over 30 sec to 10 min. Dose may be repeated at 2-, 4- or 6-hr intervals. Ped patient Initially 0.56-8 mg/kg daily in 3 or 4 divided doses (20-240 mg/m2 daily).
Hypersensitivity. Systemic fungal infection, idiopathic thrombocytopenic purpura. Intrathecal administration.
Special Precautions
Avoid deltoid muscle inj. Not for treatment of traumatic brain injury. Not to be used IA, intrabursally or for intratendinous & epidural administration for local effect. Not to be used in cerebral malaria & active ocular herpes simplex. Discontinue use in Kaposi's sarcoma patients. Corticosteroid effects. Recent MI. Susceptibility to infections. Exacerbated systemic fungal & intercurrent infections. Known or suspected Strongyloides (threadworm) infestation. Active or latent TB, posterior subcapsular cataracts, glaucoma. CHF, HTN, active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses & non-specific ulcerative colitis, osteoporosis, myasthenia gravis. Aggravated existing emotional instability or psychotic tendencies. Pheochromocytoma. Not recommended in optic neuritis. Dietary salt restriction & K supplementation. Not to be used w/ live or live, attenuated vaccine. Monitor IOP in therapy >6 wk. Avoid abrupt w/drawal. Avoid exposure to chicken pox or measles. May affect ability to drive & use machines. Renal insufficiency; cirrhosis. Pregnancy & lactation. Elderly.
Adverse Reactions
Allergic reactions; leukocytosis; CV, dermatologic, endocrinal, GI, ophth reactions; fluid & electrolyte disturbances; -ve nitrogen balance; musculoskeletal, neurologic/psychiatric disorders.
Drug Interactions
Loss of corticosteroid-induced adrenal suppression w/ aminoglutethimide. Development of hypokalemia w/ K-depleting agents. Decreased clearance w/ macrolide antibiotics. Severe weakness in myasthenia gravis patients w/ anticholinesterases. Inhibition of response to warfarin. Increased blood glucose conc by antidiabetics. Decreased INH serum conc. Increased clearance by cholestyramine. Increased activity of both cyclosporine & corticosteroids. Increased risk of arrhythmias due to hypokalemia w/ digitalis glycosides. Decreased hepatic metabolism w/ estrogens eg, OCs. Enhanced metabolism by hepatic enzyme inducers eg, barbiturates, phenytoin, carbamazepine, rifampin. Increased plasma conc w/ hepatic enzyme inhibitors. Increased salicylate clearance.
MIMS Class
Corticosteroid Hormones
ATC Classification
H02AB09 - hydrocortisone ; Belongs to the class of glucocorticoids. Used in systemic corticosteroid preparations.
Solu-Cortef inj 100 mg/2 mL
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in